What is ArriVent BioPharma, Inc.'s earnings yield?

ArriVent BioPharma, Inc. (AVBP) reported earnings yield of -14.2% in Q1 2026.

How has ArriVent BioPharma, Inc.'s earnings yield changed year-over-year?

ArriVent BioPharma, Inc.'s earnings yield increased by 29.7% year-over-year, from -20.3% to -14.2%.

What does earnings yield mean?

Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.

ArriVent BioPharma, Inc. AVBP Earnings yield

Earnings yield at other companies

Johnson & JohnsonJNJ

3.6%-1.9pp

Syndax PharmaceuticalsSNDX

-11.8%-4.5pp

Nuvation BioNUVB

-9.8%-4.6pp

ImmunomeIMNM

-9.1%-3.9pp

Arcus BiosciencesRCUS

-13.6%-5.7pp

Erasca, Inc.ERAS

-5.5%-2.6pp

Other financials

Income statement

See full

Operating income-$46.1M+30.9%

Net income-$43.3M+32.7%

EPS (diluted)-$0.96+49.5%

Balance sheet

See full

Cash & equivalents$62.1M+24.5%

Total debt$419.0K+204%

Total equity$324.0M+60.0%

Total assets$349.3M+62.1%

Cash flow

See full

Operating cash flow-$41.9M+38.4%

Valuation

See full

Market cap$1.57B+62.1%

Enterprise value$1.51B+65.4%

Returns & leverage

See full

Return on equity-55.2%+8.0pp

Debt / equity0×0.0×

Current ratio14×-0.4×

Where this comes from

Calculated from ArriVent BioPharma, Inc.’s reported figures.

net income/market cap=-14.2%

Based on trailing twelve months.

The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about ArriVent BioPharma, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ArriVent BioPharma, Inc.'s earnings yield?: ArriVent BioPharma, Inc. (AVBP) reported earnings yield of -14.2% in Q1 2026.
How has ArriVent BioPharma, Inc.'s earnings yield changed year-over-year?: ArriVent BioPharma, Inc.'s earnings yield increased by 29.7% year-over-year, from -20.3% to -14.2%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.